263 related articles for article (PubMed ID: 30056362)
1. Tumefactive multiple sclerosis lesions associated with fingolimod treatment: Report of 5 cases.
Sánchez P; Meca-Lallana V; Vivancos J
Mult Scler Relat Disord; 2018 Oct; 25():95-98. PubMed ID: 30056362
[TBL] [Abstract][Full Text] [Related]
2. Tumefactive demyelinating lesions: A comprehensive review.
Algahtani H; Shirah B; Alassiri A
Mult Scler Relat Disord; 2017 May; 14():72-79. PubMed ID: 28619436
[TBL] [Abstract][Full Text] [Related]
3. Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.
Hatcher SE; Waubant E; Nourbakhsh B; Crabtree-Hartman E; Graves JS
JAMA Neurol; 2016 Jul; 73(7):790-4. PubMed ID: 27135594
[TBL] [Abstract][Full Text] [Related]
4. Severe Exacerbation of Multiple Sclerosis Following Withdrawal of Fingolimod.
Fragoso YD; Adoni T; Gomes S; Goncalves MVM; Parolin LF; Rosa G; Ruocco HH
Clin Drug Investig; 2019 Sep; 39(9):909-913. PubMed ID: 31152369
[TBL] [Abstract][Full Text] [Related]
5. Unexpected high multiple sclerosis activity after switching from fingolimod to alemtuzumab.
Bernard-Valnet R; Pignolet B; Biotti D; Ciron J; Lafontan JF; Dumas H; Bonneville F; Brassat D
Mult Scler Relat Disord; 2018 Oct; 25():216-218. PubMed ID: 30114625
[TBL] [Abstract][Full Text] [Related]
6. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
[TBL] [Abstract][Full Text] [Related]
7. Disease Exacerbation after the Cessation of Fingolimod Treatment in Japanese Patients with Multiple Sclerosis.
Sato K; Niino M; Kawashima A; Yamada M; Miyazaki Y; Fukazawa T
Intern Med; 2018 Sep; 57(18):2647-2655. PubMed ID: 29709955
[TBL] [Abstract][Full Text] [Related]
8. Tumefactive multiple sclerosis lesions in two patients after cessation of fingolimod treatment.
Faissner S; Hoepner R; Lukas C; Chan A; Gold R; Ellrichmann G
Ther Adv Neurol Disord; 2015 Sep; 8(5):233-8. PubMed ID: 26557898
[TBL] [Abstract][Full Text] [Related]
9. Rebound of multiple sclerosis activity after fingolimod withdrawal due to planning pregnancy: Analysis of predisposing factors.
Sepúlveda M; Montejo C; Llufriu S; Sola-Valls N; Reyes D; Martinez-Lapiscina EH; Zubizarreta I; Pulido-Valdeolivas I; Martinez-Hernandez E; Ariño H; Baños N; Saiz A; Blanco Y
Mult Scler Relat Disord; 2020 Feb; 38():101483. PubMed ID: 31734621
[TBL] [Abstract][Full Text] [Related]
10. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.
He A; Spelman T; Jokubaitis V; Havrdova E; Horakova D; Trojano M; Lugaresi A; Izquierdo G; Grammond P; Duquette P; Girard M; Pucci E; Iuliano G; Alroughani R; Oreja-Guevara C; Fernandez-Bolaños R; Grand'Maison F; Sola P; Spitaleri D; Granella F; Terzi M; Lechner-Scott J; Van Pesch V; Hupperts R; Sánchez-Menoyo JL; Hodgkinson S; Rozsa C; Verheul F; Butzkueven H; Kalincik T;
JAMA Neurol; 2015 Apr; 72(4):405-13. PubMed ID: 25665031
[TBL] [Abstract][Full Text] [Related]
11. Severe disease exacerbations in patients with multiple sclerosis after discontinuing fingolimod.
Członkowska A; Smoliński Ł; Litwin T
Neurol Neurochir Pol; 2017; 51(2):156-162. PubMed ID: 28209440
[TBL] [Abstract][Full Text] [Related]
12. Severe rebound after withdrawal of fingolimod treatment in patients with multiple sclerosis.
Gündüz T; Kürtüncü M; Eraksoy M
Mult Scler Relat Disord; 2017 Jan; 11():1-3. PubMed ID: 28104247
[No Abstract] [Full Text] [Related]
13. Clinical activity after fingolimod cessation: disease reactivation or rebound?
Frau J; Sormani MP; Signori A; Realmuto S; Baroncini D; Annovazzi P; Signoriello E; Maniscalco GT; La Gioia S; Cordioli C; Frigeni B; Rasia S; Fenu G; Grasso R; Sartori A; Lanzillo R; Stromillo ML; Rossi S; Forci B; Cocco E;
Eur J Neurol; 2018 Oct; 25(10):1270-1275. PubMed ID: 29851435
[TBL] [Abstract][Full Text] [Related]
14. Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis.
Nygaard GO; Torgauten H; Skattebøl L; Høgestøl EA; Sowa P; Myhr KM; Torkildsen Ø; Celius EG
Mult Scler Relat Disord; 2022 Jun; 62():103812. PubMed ID: 35462167
[TBL] [Abstract][Full Text] [Related]
15. Different MRI patterns in MS worsening after stopping fingolimod.
Lapucci C; Baroncini D; Cellerino M; Boffa G; Callegari I; Pardini M; Novi G; Sormani MP; Mancardi GL; Ghezzi A; Zaffaroni M; Uccelli A; Inglese M; Roccatagliata L
Neurol Neuroimmunol Neuroinflamm; 2019 Jul; 6(4):e566. PubMed ID: 31086807
[TBL] [Abstract][Full Text] [Related]
16. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial.
Calkwood J; Cree B; Crayton H; Kantor D; Steingo B; Barbato L; Hashmonay R; Agashivala N; McCague K; Tenenbaum N; Edwards K
BMC Neurol; 2014 Nov; 14():220. PubMed ID: 25424122
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of sphingosine-1-phosphate receptors on reactive astrocytes drives neuropathology of multiple sclerosis rebound after fingolimod discontinuation.
Giordana MT; Cavalla P; Uccelli A; Laroni A; Bandini F; Vercellino M; Mancardi G
Mult Scler; 2018 Jul; 24(8):1133-1137. PubMed ID: 29708466
[TBL] [Abstract][Full Text] [Related]
18. Multiple sclerosis treatment with fingolimod: profile of non-cardiologic adverse events.
Fragoso YD
Acta Neurol Belg; 2017 Dec; 117(4):821-827. PubMed ID: 28528469
[TBL] [Abstract][Full Text] [Related]
19. The Effect of Fingolimod on Conversion of Acute Gadolinium-Enhancing Lesions to Chronic T1 Hypointensities in Multiple Sclerosis.
Oommen VV; Tauhid S; Healy BC; Chua AS; Malik MT; Diaz-Cruz C; Dupuy SL; Weiner HL; Chitnis T; Bakshi R
J Neuroimaging; 2016; 26(2):184-7. PubMed ID: 26445919
[TBL] [Abstract][Full Text] [Related]
20. Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series.
Delgado S; Hernandez J; Tornes L; Rammohan K
BMC Neurol; 2021 Feb; 21(1):48. PubMed ID: 33530945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
